Stocks · News reference
Vanda Pharmaceuticals Affirms FY2026 Sales Guidance of $240.000M-$290.000M vs $262.154M Est
Vanda Pharmaceuticals (NASDAQ:VNDA) affirms FY2026 sales outlook from $240.000 million-$290.000 million to $240.000 million-$290.000 million vs $262.154 million estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 8:05 PM
- Checked
- Aug 5, 2026, 8:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12
B. Riley Securities analyst Madison El-Saadi reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $17 to $12.
Read original at benzingaHC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $21 to $20.
Read original at benzingaVanda Pharma Q2 EPS $(1.04) Misses $(0.59) Estimate, Sales $50.529M Miss $61.925M Estimate
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.59) by 76.27 percent. This is a 126.09 percent decrease over losses of $(0.46) per share from
Read original at benzinga